Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to... Read More

Toronto, Ontario--(Newsfile Corp. - April 2, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that patient recruitment for its minimal residual disease ("MRD") clinical trial has been initiated, with... Read More

Toronto, Ontario--(Newsfile Corp. - February 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "Telo") is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma ("MM") disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada.... Read More

Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo" ) is pleased to announce that it has engaged Trusted Health Advisors (THA), a market leader specialized in guiding commercialization programs of innovative diagnostics products in the USA. THA will work with Telo's team to refine and accelerate Telo's go-to-market and partnership deployment plan,... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical advisory board (the "Advisory Board"). Driven by the progress of TELO's clinical studies announced on September 14, 2022, and as part of... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints. In July 2022, the Company announced that it had... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been... Read More

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ( the "Company" or "TELO") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology... Read More